Overview

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1 dose-escalation study followed by a 3-arm expansion cohort of Oraxol administered in combination with pembrolizumab.
Phase:
Phase 1
Details
Lead Sponsor:
Athenex, Inc.
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Pembrolizumab